drugset
drugset / Trial / NCT03282851

Pharmacokinetics/Pharmacodynamics (PK/PD) Equivalence Study of MSB11456

NCT03282851 ↗

Phase 1 Completed 696 enrolled Fresenius Kabi SwissBioSim GmbH
RandomizedParallel-groupDouble-blindBasic science

Summary

This study aims to compare the PK/PD of a single injection of investigational Medicinal Product (IMP) MSB11456, US licensed Actemra and EU approved RoActemra in healthy adult subjects.

Timeline

Start
2017-11-27
Primary completion
2019-10-01
Completion
2019-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject MSB11456 Unknown — Other
Comparator Tocilizumab Monoclonal antibody — Other

Indications

No indication recorded.